Kolon FnC to Shut Down Menswear Brand Amofre Following Contract Expiry with Jo Se-ho

Reporter Paul Lee / approved : 2025-12-24 03:04:59
  • -
  • +
  • 인쇄

Kolon FnC has decided to discontinue Amofre, a menswear brand it launched in 2021 in collaboration with television personality Jo Se-ho. The photo shows a fashion editorial featuring Jo Se-ho as the brand’s model at the time of its launch in 2021. (Photo courtesy of Kolon FnC)

 

 

[Alpha Biz= Paul Lee] Kolon FnC has decided to discontinue Amofre, a menswear brand in which television personality Jo Se-ho participated as creative director. The company stated that the decision was made following the expiration of the brand operation contract and is unrelated to recent controversies surrounding Jo.

According to industry sources on December 23, Kolon FnC will terminate Amofre after the 2025 fall/winter season as its contract with Jo expires at the end of this month. The company has already removed Amofre’s sales page from its official website, signaling the start of brand closure procedures.

Launched in 2021, Amofre gained attention for its focus on designs tailored to the “average Korean male body type,” including ready-to-wear trousers requiring no alterations. Jo Se-ho was involved throughout the brand’s development and marketing process.

Speculation has emerged that recent allegations involving Jo may have influenced the decision. However, Kolon FnC emphasized that the shutdown was a pre-planned move based solely on the contract’s expiration.

 

 

Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)

어플

주요기사

Stellantis Considers Exit from U.S. Battery Joint Venture 'StarPlus Energy' with Samsung SDI2026.02.11
Yanolja Becomes Largest Shareholder of Modetour Ahead of General Shareholder Meeting2026.02.11
Court Acquits Sampyo Group Chairman in Landmark Serious Accidents Punishment Act Case; Labor Unions Decry "License to Kill"2026.02.11
Court Acquits LG Welfare Foundation CEO Koo Yeon-kyung and Husband Yoon Kwan in Insider Trading Case2026.02.11
Concerns Grow Over Possible Drug Mix-Up in Daewoong Pharmaceutical’s Hypertension Medicine as Recall Details Remain Unclear2026.02.11
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사